拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析

蔡和平; 王卓

doi:10.3969/j.issn.1006-0111.2014.01.006

拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析

doi: 10.3969/j.issn.1006-0111.2014.01.006

蔡和平,
王卓

第二军医大学附属长海医院药学部, 上海 200433

基金项目: 2012医院药学科研专项:肿瘤药学(No.2012-YY-01-04).

Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

Department of Pharmacy, Changhai Hospital Afilliated to Second Military Medical University, Shanghai 200433, China

摘要: 目的用荟萃(Meta)分析法比较拓扑替康两种治疗方案的临床疗效和安全性,为临床医生在选择化疗方案时提供参考依据。方法收集自PubMed建库至2013年7月10日发表的有关比较拓扑替康两种治疗方案有效性和不良反应发生率的文献,根据Meta分析的要求对检索到的原始文献进行质量评估,对符合要求的所有文献研究结果进行Meta分析,评估两种化疗方案对小细胞肺癌治疗的有效性和安全性。结果有3篇文献符合纳入标准,在评价两组方案对患者有效率中总样本量为288例,其中周疗方案组165例,有效17例;标准方案组123例,有效21例。在评价两组方案对患者不良反应发生率中纳入 2篇文献,总样本量132例,其中周疗方案组89例,Ⅲ/Ⅳ级粒细胞减少26例,Ⅲ/Ⅳ级血红蛋白减少17例,Ⅲ/Ⅳ级血小板减少18例;标准方案组43例,Ⅲ/Ⅳ级粒细胞减少发生39例,Ⅲ/Ⅳ级血红蛋白减少24例,Ⅲ/Ⅳ级血小板减少32例。两组方案对患者有效率影响中OR=0.49,95%可信区间0.23~1.01,跨过无效线;两组方案对患者Ⅲ/Ⅳ级粒细胞减少发生率的影响中OR=0.04,95%可信区间0.01~0.14,位于无效线的左侧;两组方案对患者Ⅲ/Ⅳ级血红蛋白减少发生率的影响中OR=0.27,95%可信区间0.11~0.63,位于无效线的左侧;两组方案对患者Ⅲ/Ⅳ级血小板减少发生率的影响中OR=0.12,95%可信区间0.04~0.32,位于无效线的左侧。结论两种化疗方案在有效率方面的差异无统计学意义;周疗方案组在Ⅲ/Ⅳ级粒细胞减少的发生率、Ⅲ/Ⅳ血红蛋白减少的发生率低和Ⅲ/Ⅳ血小板减少的发生率等方面均低于标准方案组,差异有统计学意义。
- 拓扑替康 /
- 标准方案 /
- 周疗方案 /
- Meta分析
Abstract: Objective To compare the effect and safety of the two regimens of topotecan by means of Meta-analysis, in order to give evidences for doctors when selecting regimens. Methods All the studies that have been searched in Pub Med from setup data base to 2013-07-10 were evaluated strictly and meta-analysis was used to study the effect and safety of two regimens contain standard regimens and weekly regimens. The odds radio(OR) was calculate for incidence of efficiency and safety of two regimens. Results Totally 3 studies including 288 cases were analyzed in efficiency. 17 cases were effective in 165 cases of weekly regimens; 21 cases were effective in 123 cases of standard regimens. Totally 2 studies including 132 cases were analyzed in safety. 89 cases were in weekly regimens. Of which 26 cases of Ⅲ/Ⅳ neutropenia and 17cases of Ⅲ/Ⅳ low-hemoglobin and 32 cases of Ⅲ/Ⅳ thrombopenia. 43 cases were in standard regimens. Of which 39 cases of Ⅲ/Ⅳ neutropenia and 24 cases of Ⅲ/Ⅳ low-hemoglobin and 32 cases of Ⅲ/Ⅳ thrombopenia. The pooled OR of efficiency was 0.49 with a 95% confidence interval(0.23-1.01);the pooled OR of Ⅲ/Ⅳ neutropenia was 0.04 with a 95% confidence interval(0.01-0.14); the pooled OR of Ⅲ/Ⅳ low-hemoglobin was 0.27 with a 95% confidence interval(0.11-0.63); the pooled OR of Ⅲ/Ⅳ thrombopenia was 0.12 with a 95% confidence interval(0.04-0.32). Conclusion Weekly regimens group compared to standard regimens group in efficiency had no statistical significance; Weekly regimens group compared to standard regimens group for preventing Ⅲ/Ⅳ neutropenia, Ⅲ/Ⅳ low-hemoglobin and Ⅲ/Ⅳ thrombopenia had statistical significance. Weekly regimens group was better to standard regimens group for preventing Ⅲ/Ⅳ neutropenia, Ⅲ/Ⅳ low-hemoglobin and Ⅲ/Ⅳ thrombopenia.
- topotecan /
- standard regimens /
- weekly regimens /
- meta-analysis

[1]	Tomicic MT, Christmann M, Kaina B.Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival[J].Cancer Res,2005,65(19):8920-8926.
[2]	Armstrong DK, Spriggs D, Levin J, et al.Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer:an integrated analysis[J].Oncologist,2005,10(9):686-694.
[3]	Gordon AN, Fleagle JT, Guthrie D,et al.Recurrent epithelial ovarian carcinoma:a randomized phaseⅢ study of pegylated liposomal doxorubicin versus topotecan[J].J Clin Oncol,2001,19(14):3312-3322.
[4]	Vandenput I, Amant F, Neven P, et al.Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer[J].Int J Gynecol Cancer,2007,17(1):83-87.
[5]	Abushahin F, Singh DK, Lurain JR,et al.Weekly topotecan for recurrent platinum resistant ovarian cancer[J].Gynecol Oncol,2008,108(1):53-57.
[6]	Herzog TJ, Sill MW, Walker JL, et al.A phase Ⅱ study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer:a gynecologic oncology group study (GOG 146Q)[J].Gynecol Oncol,2011,120(3):454-458.
[7]	Sehouli J, Stengel D, Harter P,et al.Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer:a randomized multicenter phase Ⅱ trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group[J].J Clin Oncol,2011,29(2):242-248.
[8]	刘勇,席青松,赵荆,等.两种方案治疗难治/耐药型小细胞肺癌比较[J].药物与临床,2011,30(5):598-601.

[1]	李锐, 张倩倩, 王瑞冬, 高小峰. 国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(2): 1-6. doi: 10.12206/j.issn.2097-2024.202408031
[2]	黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉. 耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
[3]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[4]	史生辉, 石飞, 雷琼, 王亚峰, 吴雪花. 青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
[5]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[6]	刘依秦, 王超群, 邱娇娜. 胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
[7]	瞿文君, 白若楠, 崔力, 周琰. 基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
[8]	宋红卫, 王燕, 方铭, 马云鹏, 钟超, 徐一新, 徐峰, 周婷. 2021−2023年我院药品不良反应的特点分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404041
[9]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[10]	尹小娟, 台力丽, 肖俊峰, 季波. 铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
[11]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[12]	姚瑞阳, 于海征, 李耀盺, 张磊. 丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
[13]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[14]	凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋. 星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
[15]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[16]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
[17]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[18]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044

点击查看大图

计量

文章访问数: 2424
HTML全文浏览量: 235
PDF下载量: 88
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析

doi: 10.3969/j.issn.1006-0111.2014.01.006

Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

计量

拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析

doi: 10.3969/j.issn.1006-0111.2014.01.006

第二军医大学附属长海医院药学部, 上海 200433

English Abstract

Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

Department of Pharmacy, Changhai Hospital Afilliated to Second Military Medical University, Shanghai 200433, China

全文HTML

目录

留言板

拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析

doi: 10.3969/j.issn.1006-0111.2014.01.006

Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

计量

出版历程

拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析

doi: 10.3969/j.issn.1006-0111.2014.01.006

第二军医大学附属长海医院药学部, 上海 200433

English Abstract

Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

Department of Pharmacy, Changhai Hospital Afilliated to Second Military Medical University, Shanghai 200433, China

全文HTML

目录